ArticleDiabetes spectrum : a publication of the American Diabetes Association2021
Clinical Application of Time in Range and Other Metrics.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.Diabetologia · 2026Trial
- Patient satisfaction and performance of the A8+ TouchCare Nano in children and adolescents with type 1 diabetes mellitus.World journal of clinical pediatrics · 2026Article
- Effects of Menstrual Cycle on Insulin Sensitivity in Type 1 Diabetes: An Observational Study of Individuals Using an Automated Insulin Delivery System.Diabetes care · 2026Observational
- Evaluating Time in Range for Visual Acuity and Macular Thickness as Outcome Measures for Randomized Clinical Trials.Translational vision science & technology · 2026Article
- The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.The Journal of clinical endocrinology and metabolism · 2026Article
- Personalized Type 1 Diabetes Management: Reinforcement Learning-Based Insulin Dosing and Glucose Forecasting.JMIR diabetes · 2026Article
- A region-wide hub and spoke approach to standardize and decentralize type 1 diabetes management.Frontiers in public health · 2026Observational
- What do LLMs value? An evaluation framework for revealing subjective trade-offs in assessment of glycemic control.Proceedings of machine learning research · 2025Article
- Future of diabetic foot risk: Unveiling predictive continuous glucose monitoring biomarkers.World journal of diabetes · 2025Article
- Article
- Relation of time in range to severity of coronary artery disease in patients with type 2 diabetes: A cross-sectional study.Open medicine (Warsaw, Poland) · 2025Article
- Assessment of Glycemia Risk Index and Standard Continuous Glucose Monitoring Metrics in a Real-World Setting of Exercise in Adults With Type 1 Diabetes: A Post-Hoc Analysis of the Type 1 Diabetes and Exercise Initiative.Journal of diabetes science and technology · 2024Article
- Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Review
- Letter to the Editor Regarding "Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels".Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.Journal of diabetes science and technology · 2023Article
- Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Article
- Impact of the KARAZ platform's behavioral interventions and incentives on diabetic glycemic control in Saudi Arabia.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Time in range (TIR) and other continuous glucose monitoring (CGM)-derived metrics have been standardized in international consensus conferences. TIR correlates closely with A1C; a TIR of 70% correlates to an A1C of 6.7-7%. Evidence is emerging on the association of TIR with long-term diabetes complications, and each 10% increase in TIR shows a substantial decrease in risk for long-term complications. Application of TIR to clinical practice can be easily done with a stepped approach to the analysis and interpretation of CGM-derived metrics and the ambulatory glucose profile report. Clinician education and partnership with patients are crucial for successful implementation of TIR and all CGM-derived metrics in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.